Contineum Therapeutics Q3 net loss $12.8M, cash $182.4M, pipeline milestones affirmed

Contineum Therapeutics, Inc.

Cash, cash equivalents and marketable securities $182.4M; projected cash runway extended through 2028.
Net loss $12.8M vs $10.3M in prior-year quarter; R&D expenses $11.0M (+13% YoY).
Generated $19.0M from ATM offerings of 3.2M shares at weighted avg $6.04/share.
Topline data from PIPE-307 Phase 2 VISTA RRMS trial expected Q4 2025; global Phase 2 for PIPE-791 IPF to initiate Q4 2025.
Deferred initiation of PIPE-791 PrMS and CTX-343 trials to extend cash runway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.